Home >  News >  Industry >  Pharma News >  Molbio Diagnostics...

Molbio Diagnostics unveils Herpes Simplex Virus test 'Truenat HSV-1/2'

By - Ruchika Sharma
Published On 2023-01-04 09:29 GMT   |   Update On 2023-01-04 09:29 GMT
Advertisement

New Delhi: Molbio Diagnostics has launched the Truenat HSV 1/2 for testing the Herpes Simplex Virus. The test is approved by CDSCO and can provide sample-to-test results in an hour's time. The Real-Time PCR test works on the existing Truelab infrastructure and doesn't require any additional setup and equipment to run the test, making it possible to test at resource-limited settings.

Infection with herpes simplex virus (HSV), known as herpes, is common globally. HSV infections are classified into two types: HSV-1 and HSV-2. They can be spread when an infected person begins shedding the virus. HSV-1 is mainly transmitted by oral-to-oral contact to cause oral herpes which can include symptoms known as “cold sores”, but can also cause genital herpes. HSV-2 is a sexually transmitted infection that causes genital herpes.
Advertisement
Both HSV-1 and HSV-2 are lifelong infections. Herpes infections are most contagious when symptoms are present, although they can still spread to other people if no symptoms appear. Infection with HSV-2 increases the risk of acquiring and transmitting HIV infection. Further, Herpes (HSV-1 and HSV-2) can also be transmitted from mother to child during delivery in rare cases that can lead to lasting neurologic disability or death.
According to WHO’s 2022 report, an estimated 3.7 billion people under age 50 (67%) have HSV-1 infection, and an estimated 491 million people aged 15–49 (13%) have HSV-2 infection worldwide. People with HSV - 1 are not at risk of reinfection but they are at risk of acquiring HSV-2 infection which increases the risk of HIV in patients by two or threefold.
Commenting on the launch, Mr. Sriram Natarajan, CEO, Founder, and Director, of Molbio Diagnostics, said, “HSV is an infectious disease that the world has been fighting for a long time. Testing for HSV infection can help to reduce infection rates by promoting education and awareness, as well as, to some extent, removing the stereotype associated with the disease. We at Molbio will continue to develop such products and technologies in order to ensure a more promising future in healthcare.’"
Also commenting on the launch, Dr. Chandrasekhar Nair, CTO, and Director, of Molbio Diagnostics, said, “HSV is rarely addressed, and currently there is no cure. So, as the first step in preventing the disease's spread, we need an effective method of testing at the point of care that is both cost-effective and provides accurate test results. Molbio's Truenat HSV1/2 can ensure an easy and accurate diagnosis of the infection and thus leading to timely initiation of the treatment."
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Akums Drugs, Zambia Govt Ink USD 50 Mn Medicine Supply Deal, Pharma Plant by 2028

USFDA Suspends Ixchiq Chikungunya Vaccine License Citing Encephalitis Death, 20+ Serious Adverse Events

Aurobindo Pharma's subsidiary CuraTeQ Biologics Secures MHRA Approval for Trastuzumab Biosimilar Dazublys in HER2-Positive Cancer

Royalty Pharma to Buy USD 950 Million Royalty Stake in Amgen's Small Cell Lung Cancer Drug Imdelltra

Sun Pharma Wins CDSCO Panel Approval for Phase III Vitiligo Trial of Ruxolitinib Cream

Chhattisgarh Pharma Firm Slapped Recall Notice Over Defective Paracetamol Tablets

Crime Branch Busts Illegal Psychotropic Drug Trade, Pharmacist Among 3 Held

Delhi HC Cancels UNKIND Trademark, Upholds Mankind Pharma's KIND Family Rights